Neuroprotective therapy cleared by FDA for testing in acute MS relapses

Privosegtor already being developed to treat a common MS symptom

Written by Patricia Inacio, PhD |

In this illustration, a clinician holds a clipboard while pointing to the words

Oculis is expanding the clinical development of privosegtor, its experimental nerve-protecting therapy, to include the treatment of acute relapses in people with multiple sclerosis. (Illustration from iStock)

  • Oculis received FDA clearance to test its experimental neuroprotective therapy for treating acute MS relapses.
  • Privosegtor is designed to protect nerve cells from damage and support functional recovery during acute attacks.
  • Oculis plans to share more details about its clinical development strategy for acute MS relapse next month.

Oculis is expanding the clinical development of privosegtor, its experimental nerve-protecting therapy, to include the treatment of acute relapses in people with multiple sclerosis (MS).

The move follows the U.S. Food and Drug Administration’s (FDA) clearance of an investigational new drug (IND) application, paving the way for clinical trials in this new indication.

Privosegtor was already being developed to treat optic neuritis, a condition marked by inflammation of the optic nerve that carries visual information from the eye to the brain. Optic neuritis is a common symptom of MS that often occurs during MS relapses.

Oculis plans to share more details about its clinical development strategy for acute MS relapses, alongside updates on its ongoing PIONEER clinical program for optic nerve disorders, at a research and development day on Dec. 8.

“This IND clearance marks a pivotal new era for Oculis in neurology as we advance Privosegtor from optic neuritis into acute MS relapses, addressing a high-unmet-need setting with no currently approved neuroprotective therapies,” Riad Sherif, MD, CEO of Oculis, said in a company press release.

Recommended Reading
A researcher seated at a desk with a computer and microscope reads data on a tablet.

MS therapy preserves cognitive function over 4 years, study shows

Privosegtor improved visual function in optic neuritis trial

MS is caused by an abnormal immune response that damages the brain and spinal cord, disrupting nerve signaling and leading to a range of neurological symptoms.

In relapsing forms of MS, patients experience periods of new or worsening symptoms, known as relapses, followed by periods of partial or complete recovery. However, damage sustained during relapses may not fully resolve, potentially contributing to disability accumulation over time.

Disease-modifying therapies can help reduce the frequency of relapses and corticosteroids are commonly used to speed recovery and shorten their duration. However, no therapies are specifically designed to protect nerve cells from damage during an acute MS relapse.

Privosegtor is a small molecule designed to protect nerve cells, potentially limiting permanent damage and promoting recovery after an inflammatory attack. The therapy is capable of crossing the blood-brain barrier, which regulates which substances can cross from the bloodstream into the brain, as well as barriers protecting the retina, the light-sensitive tissue at the back of the eye.

Because optic neuritis is a common manifestation of MS relapse, our positive Phase 2 ACUITY results give us confidence in Privosegtor’s potential to limit neuroaxonal damage and support functional recovery following an acute attack.

The rationale for testing privosegtor in MS relapses is supported by findings from the completed Phase 2 ACUITY trial (NCT04762017), which evaluated the therapy in people with acute optic neuritis, with or without MS.

Results showed that privosegtor, given on top of standard-of-care corticosteroids, improved visual function compared with steroids plus a placebo, and helped preserve layers of the retina containing nerve cells and their fibers. Treatment also lowered blood levels of neurofilament light chain, a marker of nerve fiber damage, and glial fibrillary acidic protein, a marker of activation of nervous system support cells called astrocytes.

“Because optic neuritis is a common manifestation of MS relapse, our positive Phase 2 ACUITY results give us confidence in Privosegtor’s potential to limit neuroaxonal damage and support functional recovery following an acute attack,” Sherif said.

Recommended Reading
Assorted pills and capsules surrounding a magnifying glass on a light blue background.

Experimental MS therapy outperforms approved treatment in two trials

FDA supports proposed clinical strategy for therapy

Ahead of the new IND submission, the FDA agreed that Oculis could use data from its existing clinical development program in optic neuritis to support the development of privosegtor for acute MS relapses.

The agency also supported the company’s proposed clinical strategy, which would include MS patients experiencing optic neuritis as well as other types of relapses, including those affecting walking ability.

In the upcoming trial, patients will receive 3 mg/kg of privosegtor daily for five consecutive days. The main measure of treatment efficacy will be assessed as early as three months.

This is the same dose being evaluated in PIONEER-1 (NCT07623668), the first of two registrational trials that Oculis is conducting to potentially support an approval for privosegtor in optic neuritis. The Phase 3 trial began treating patients in August.

“Even with effective immunomodulating therapies, many people with MS still experience relapses, and recovery from them is often incomplete. A treatment that protects neurons … during an acute relapse would fill a gap that no current care addresses. I am encouraged to see Privosegtor moving toward clinical development in acute MS relapses and beyond and look forward to seeing how the data evolve,” said Amit Bar-Or, MD, a professor of neurology and chief of the MS division at the University of Pennsylvania’s Perelman School of Medicine.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.